<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39400005</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>14</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1532-2092</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>03</Day></PubDate></JournalIssue><Title>Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology</Title><ISOAbbreviation>Europace</ISOAbbreviation></Journal><ArticleTitle>Comprehensive vs. standard remote monitoring of cardiac resynchronization devices in heart failure patients: results of the ECOST-CRT study.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">euae233</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/europace/euae233</ELocationID><Abstract><AbstractText Label="AIMS" NlmCategory="OBJECTIVE">Integrating remote monitoring (RM) into existing healthcare practice for heart failure (HF) patients to improve clinical outcome remains challenging. The ECOST-CRT study compared the clinical outcome of a comprehensive RM scheme including a patient questionnaire capturing signs and symptoms of HF and notifications for HF specific parameters to traditional RM in patients with cardiac resynchronization therapy (CRT) devices.</AbstractText><AbstractText Label="METHODS AND RESULTS" NlmCategory="RESULTS">Patients were randomized 1:1 to standard daily RM (notification for technical parameters and ventricular arrhythmias; control group) or comprehensive RM (adding a monthly symptom questionnaire and notifications for biventricular pacing, premature ventricular contraction, atrial arrhythmias; active group). The primary endpoint was all-cause mortality or hospitalization for worsening HF (WHF). Six hundred fifty-two patients (70.4 ± 10.3 years, 73% men, left ventricular ejection fraction 29.1 ± 7.6%, 68% CRT-Defibrillators, 32% CRT-Pacemakers) were enrolled. The COVID-19 pandemic caused an early termination of the study, so the mean follow-up duration was 18 ± 8 months. No statistically significant difference in the primary endpoint was found between the groups [59 (18.3%) control vs. 77 (23.3%) active group; log-rank test P = 0.13]. Among the secondary endpoints, the MLHF questionnaire showed a larger share of patients with improvement of quality of life compared to baseline in the active group (78%) vs. control (61%; P = 0.03).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The study does not support the notion that comprehensive RM, when compared to standard RM, in HF patients with CRT improves the clinical outcome of all-cause mortality or WHF hospitalizations. However, this study was underpowered due to an early termination and further trials are required.</AbstractText><AbstractText Label="REGISTRATION" NlmCategory="BACKGROUND">Clinical Trials.gov Identifier: NCT03012490.</AbstractText><CopyrightInformation>© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Klein</LastName><ForeName>Cédric</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-1189-1844</Identifier><AffiliationInfo><Affiliation>CHU Lille, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kouakam</LastName><ForeName>Claude</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>CHU Lille, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lazarus</LastName><ForeName>Arnaud</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-2276-3693</Identifier><AffiliationInfo><Affiliation>Clinique Ambroise Paré, Neuilly-sur-Seine, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Groote</LastName><ForeName>Pascal</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-6211-0147</Identifier><AffiliationInfo><Affiliation>CHU Lille, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bauters</LastName><ForeName>Christophe</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-8268-8467</Identifier><AffiliationInfo><Affiliation>Univ. Lille, Inserm, CHU Lille, Institut Pasteur, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marijon</LastName><ForeName>Eloi</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-7227-3428</Identifier><AffiliationInfo><Affiliation>Hôpital Européen Georges Pompidou, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mouquet</LastName><ForeName>Frédéric</ForeName><Initials>F</Initials><Identifier Source="ORCID">0009-0007-8276-7975</Identifier><AffiliationInfo><Affiliation>Hôpital privé Le Bois, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Degand</LastName><ForeName>Bruno</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Centre Hospitalier Universitaire Poitiers, Poitiers, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guyomar</LastName><ForeName>Yves</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0009-0002-6057-6768</Identifier><AffiliationInfo><Affiliation>Centre hospitalier Saint Philibert, Lomme, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mansourati</LastName><ForeName>Jacques</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-3051-2560</Identifier><AffiliationInfo><Affiliation>CHU Brest, Brest, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leclercq</LastName><ForeName>Christophe</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-4399-5568</Identifier><AffiliationInfo><Affiliation>CHU Rennes, Rennes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guédon-Moreau</LastName><ForeName>Laurence</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-5806-2218</Identifier><AffiliationInfo><Affiliation>CHU Lille, Univ.Lille, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>ECOST-CRT study Investigators
</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT03012490</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><Agency>Biotronik</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Europace</MedlineTA><NlmUniqueID>100883649</NlmUniqueID><ISSNLinking>1099-5129</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006333" MajorTopicYN="Y">Heart Failure</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058409" MajorTopicYN="Y">Cardiac Resynchronization Therapy Devices</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058406" MajorTopicYN="Y">Cardiac Resynchronization Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058998" MajorTopicYN="N">Remote Sensing Technology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017216" MajorTopicYN="N">Telemedicine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cardiac resynchronization therapy</Keyword><Keyword MajorTopicYN="N">Heart failure</Keyword><Keyword MajorTopicYN="N">Remote monitoring</Keyword></KeywordList><CoiStatement>Conflict of interest: C. Klein received consulting fees from Boston Scientific. L.G.-M. received consulting fees from Boston Scientific and Biotronik, and has grant support from Abbott, Medtronic, Phenix Cardiologie, Microport, and Zoll. A.L. is minor part-time employee of Biotronik France, has participated on a Data Safety Monitoring Board for Biotronik, has stock options from Implicity, and has received support for attending meetings from Boston Scientific France. P.d.G. received consulting fees from Astra Zeneca, Servier, Boehringer Ingelheim, and Bayer, and honoraria from Novartis, Astra Zeneca, Servier, BMS, Vifor, MSD, Boehringer Ingelheim, Bayer, and Pfizer. E.M. received research grants and consulting fees from Medtronic, Abbott, Boston Scientific, Biotronik, Microport, and Zoll. F.M. received consulting fees Newcard, honoraria from Novartis, BMS/Pfizer, Vifor, and Boehringer, and has received support for attending meetings from Boehringer and BMS/Pfizer. B.D. received consulting fees from Boston Scientific, Abbott, and Microport. Y.G. has received support for attending meetings from Biotronik. J.M. received consulting fees from Biotronik, Boston Scientific, Medtronic, and Microport. C.L. received consulting fees and has grant support from Biotronik, Medtronic, and Abbott. C.B. has no conflict of interests.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Guedon-Moreau</LastName><ForeName>Laurence</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Degand</LastName><ForeName>Bruno</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guyomar</LastName><ForeName>Yves</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mansourati</LastName><ForeName>Jacques</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Babuty</LastName><ForeName>Dominique</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pons</LastName><ForeName>Maxime</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guy-Moyat</LastName><ForeName>Benoit</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Deharo</LastName><ForeName>Jean-Claude</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gras</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Himbert</LastName><ForeName>Caroline</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leclercq</LastName><ForeName>Christophe</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pasquie</LastName><ForeName>Jean-Luc</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eschalier</LastName><ForeName>Romain</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marzak</LastName><ForeName>Halim</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boursier</LastName><ForeName>Michel</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jourda</LastName><ForeName>François</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anselme</LastName><ForeName>Frédéric</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gorka</LastName><ForeName>Hervé</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Billon</LastName><ForeName>Olivier</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Champ-Rigot</LastName><ForeName>Laure</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ait Said</LastName><ForeName>Mina</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Taieb</LastName><ForeName>Jérôme</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Badoz</LastName><ForeName>Marc</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Laborderie</LastName><ForeName>Julien</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Belhameche</LastName><ForeName>Mohamed</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ploux</LastName><ForeName>Sylvain</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>de Guillebon</LastName><ForeName>Maxime</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dompnier</LastName><ForeName>Antoine</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boveda</LastName><ForeName>Serge</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gomes-Ferreira</LastName><ForeName>Sophie</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Giraudeau</LastName><ForeName>Cédric</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Peyrol</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Winum</LastName><ForeName>Pierre</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gal</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blangy</LastName><ForeName>Hugues</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Le Vavasseur</LastName><ForeName>Olivier</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duparc</LastName><ForeName>Alexandre</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Forelle</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Behaghel</LastName><ForeName>Albin</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fouche</LastName><ForeName>Renaud</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Laurent</LastName><ForeName>Gabriel</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barake</LastName><ForeName>Hassan</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reuter</LastName><ForeName>Sylvain</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sultan</LastName><ForeName>Pierre</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Da Costa</LastName><ForeName>Antoine</ForeName><Initials>A</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>16</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>16</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>7</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39400005</ArticleId><ArticleId IdType="pmc">PMC11472153</ArticleId><ArticleId IdType="doi">10.1093/europace/euae233</ArticleId><ArticleId IdType="pii">7820744</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>McDonagh  TA, Metra  M, Adamo  M, Gardner  RS, Baumbach  A, Böhm  M  et al.  2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J  2021;42:3599–726.</Citation><ArticleIdList><ArticleId IdType="pubmed">34447992</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrick  AM, Raj  SR, Deneke  T, Kojodjojo  P, Lopez-Cabanillas  N, Abe  H  et al.  2023 HRS/EHRA/APHRS/LAHRS Expert Consensus Statement on Practical Management of the Remote Device Clinic. Europace  2023 May 19;25(5):euad123. doi: 10.1093/europace/euad123.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/europace/euad123</ArticleId><ArticleId IdType="pmc">PMC10199172</ArticleId><ArticleId IdType="pubmed">37208301</ArticleId></ArticleIdList></Reference><Reference><Citation>Varma  N, Braunschweig  F, Burri  H, Hindricks  G, Linz  D, Michowitz  Y  et al.  Remote monitoring of cardiac implantable electronic devices and disease management. Europace  2023;25:euad233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10451003</ArticleId><ArticleId IdType="pubmed">37622591</ArticleId></ArticleIdList></Reference><Reference><Citation>Hindricks  G, Taborsky  M, Glikson  M, Heinrich  U, Schumacher  B, Katz  A  et al.  Implant-based multiparameter telemonitoring of patients with heart failure (IN-TIME): a randomised controlled trial. Lancet  2014;384:583–90.</Citation><ArticleIdList><ArticleId IdType="pubmed">25131977</ArticleId></ArticleIdList></Reference><Reference><Citation>Geller  JC, Lewalter  T, Bruun  NE, Taborsky  M, Bode  F, Cosedis Nielsen  J  et al.  Implant-based multi-parameter telemonitoring of patients with heart failure and a defibrillator with vs. without cardiac resynchronization therapy option: a subanalysis of the IN-TIME trial. Clin Res Cardiol  2019;108:1117–27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6753058</ArticleId><ArticleId IdType="pubmed">30874886</ArticleId></ArticleIdList></Reference><Reference><Citation>Tajstra  M, Sokal  A, Gadula-Gacek  E, Kurek  A, Wozniak  A, Niedziela  J  et al.  Remote Supervision to Decrease Hospitalization Rate (RESULT) study in patients with implanted cardioverter-defibrillator. Europace  2020;22:769–76.</Citation><ArticleIdList><ArticleId IdType="pubmed">32304216</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan  JM, Kitt  S, Gill  J, McComb  JM, Ng  GA, Raftery  J  et al.  Remote management of heart failure using implantable electronic devices. Eur Heart J  2017;38:2352–60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5837548</ArticleId><ArticleId IdType="pubmed">28575235</ArticleId></ArticleIdList></Reference><Reference><Citation>Brignole  M, Auricchio  A, Baron-Esquivias  G, Bordachar  P, Boriani  G, Breithardt  OA  et al.  2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy: the task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). developed in collaboration with the European Heart Rhythm Association (EHRA). Eur Heart J  2013;34:2281–329.</Citation><ArticleIdList><ArticleId IdType="pubmed">23801822</ArticleId></ArticleIdList></Reference><Reference><Citation>Daubert  JC, Saxon  L, Adamson  PB, Auricchio  A, Berger  RD, Beshai  JF  et al.  2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management. Europace  2012;14:1236–86.</Citation><ArticleIdList><ArticleId IdType="pubmed">22930717</ArticleId></ArticleIdList></Reference><Reference><Citation>Behlouli  H, Feldman  DE, Ducharme  A, Frenette  M, Giannetti  N, Grondin  F  et al.  Identifying relative cut-off scores with neural networks for interpretation of the Minnesota Living with Heart Failure questionnaire. Annu Int Conf IEEE Eng Med Biol Soc  2009;2009:6242–6.</Citation><ArticleIdList><ArticleId IdType="pubmed">19965089</ArticleId></ArticleIdList></Reference><Reference><Citation>Bristow  MR, Saxon  LA, Boehmer  J, Krueger  S, Kass  DA, De Marco  T  et al.  Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med  2004;350:2140–50.</Citation><ArticleIdList><ArticleId IdType="pubmed">15152059</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleland  JGF, Daubert  J-C, Erdmann  E, Freemantle  N, Gras  D, Kappenberger  L  et al.  The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med  2005;352:1539–49.</Citation><ArticleIdList><ArticleId IdType="pubmed">15753115</ArticleId></ArticleIdList></Reference><Reference><Citation>Moss  AJ, Hall  WJ, Cannom  DS, Klein  H, Brown  MW, Daubert  JP  et al.  Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med  2009;361:1329–38.</Citation><ArticleIdList><ArticleId IdType="pubmed">19723701</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang  ASL, Wells  GA, Talajic  M, Arnold  MO, Sheldon  R, Connolly  S  et al.  Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med  2010;363:2385–95.</Citation><ArticleIdList><ArticleId IdType="pubmed">21073365</ArticleId></ArticleIdList></Reference><Reference><Citation>Auricchio  A, Metra  M, Gasparini  M, Lamp  B, Klersy  C, Curnis  A  et al.  Long-term survival of patients with heart failure and ventricular conduction delay treated with cardiac resynchronization therapy. Am J Cardiol  2007;99:232–8.</Citation><ArticleIdList><ArticleId IdType="pubmed">17223424</ArticleId></ArticleIdList></Reference><Reference><Citation>Gillis  AM, Kerr  CR, Philippon  F, Newton  G, Talajic  M, Froeschl  M  et al.  Impact of cardiac resynchronization therapy on hospitalizations in the Resynchronization-Defibrillation for Ambulatory Heart Failure trial. Circulation  2014;129:2021–30.</Citation><ArticleIdList><ArticleId IdType="pubmed">24610807</ArticleId></ArticleIdList></Reference><Reference><Citation>Linde  C, Gold  MR, Abraham  WT, St John Sutton  M, Ghio  S, Cerkvenik  J  et al.  Long-term impact of cardiac resynchronization therapy in mild heart failure: 5-year results from the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study. Eur Heart J  2013;34:2592–9.</Citation><ArticleIdList><ArticleId IdType="pubmed">23641006</ArticleId></ArticleIdList></Reference><Reference><Citation>Morani  G, Gasparini  M, Zanon  F, Casali  E, Spotti  A, Reggiani  A  et al.  Cardiac resynchronization therapy-defibrillator improves long-term survival compared with cardiac resynchronization therapy-pacemaker in patients with a class IA indication for cardiac resynchronization therapy: data from the Contak Italian Registry. Europace  2013;15:1273–9.</Citation><ArticleIdList><ArticleId IdType="pubmed">23439866</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruschitzka  F, Abraham  WT, Singh  JP, Bax  JJ, Borer  JS, Brugada  J  et al.  Cardiac-resynchronization therapy in heart failure with a narrow QRS complex. N Engl J Med  2013;369:1395–405.</Citation><ArticleIdList><ArticleId IdType="pubmed">23998714</ArticleId></ArticleIdList></Reference><Reference><Citation>Koehler  F, Koehler  K, Deckwart  O, Prescher  S, Wegscheider  K, Kirwan  BA  et al.  Efficacy of telemedical interventional management in patients with heart failure (TIM-HF2): a randomised, controlled, parallel-group, unmasked trial. Lancet  2018;392:1047–57.</Citation><ArticleIdList><ArticleId IdType="pubmed">30153985</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirchhof  P, Toennis  T, Goette  A, Camm  AJ, Diener  HC, Becher  N  et al.  Anticoagulation with edoxaban in patients with atrial high-rate episodes. N Engl J Med  2023;389:1167–79.</Citation><ArticleIdList><ArticleId IdType="pubmed">37622677</ArticleId></ArticleIdList></Reference><Reference><Citation>Healey  JS, Lopes  RD, Granger  CB, Alings  M, Rivard  L, McIntyre  WF  et al.  Apixaban for stroke prevention in subclinical atrial fibrillation. N Engl J Med  2024;390:107–17.</Citation><ArticleIdList><ArticleId IdType="pubmed">37952132</ArticleId></ArticleIdList></Reference><Reference><Citation>Skov  O, Johansen  JB, Nielsen  JC, Larroudé  CE, Riahi  S, Melchior  TM  et al.  Efficacy of a web-based healthcare innovation to advance the quality of life and care of patients with an implantable cardioverter defibrillator (ACQUIRE-ICD): a randomized controlled trial. Europace  2023;25:euad253.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10700011</ArticleId><ArticleId IdType="pubmed">38055845</ArticleId></ArticleIdList></Reference><Reference><Citation>Botto  GL, Sinagra  G, Bulava  A, Gargaro  A, Timmel  T, Giacopelli  D  et al.  Predicting worsening heart failure hospitalizations in patients with implantable cardioverter defibrillators: is it all about alerts? A pooled analysis of nine trials. Europace  2024;26:euae032.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10858640</ArticleId><ArticleId IdType="pubmed">38291778</ArticleId></ArticleIdList></Reference><Reference><Citation>Simovic  S, Providencia  R, Barra  S, Kircanski  B, Guerra  JM, Conte  G  et al.  The use of remote monitoring of cardiac implantable devices during the COVID-19 pandemic: an EHRA physician survey. Europace  2022;24:473–80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8499732</ArticleId><ArticleId IdType="pubmed">34410364</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>